Group 1 - The core viewpoint of the article highlights the significant stock price increase of Zhonghui Biotech-B (02627), which has risen over 20% to reach a new high of 54 HKD, marking a threefold increase from its IPO price of 12.9 HKD [1] - As of the report, the stock is up 22.65% at 53.6 HKD, with a trading volume of 43.85 million HKD and a total market capitalization exceeding 21 billion HKD [1] - The company announced that its quadrivalent influenza virus subunit vaccine, branded as Huiru Kangs, has been included in the preliminary review list of innovative drugs for national commercial health insurance, as published by the National Healthcare Security Administration on August 12 [1] Group 2 - The quadrivalent influenza virus subunit vaccine received New Drug Application (NDA) approval from the National Medical Products Administration in May 2023, making it the first and only quadrivalent influenza virus subunit vaccine approved in China until July 21, 2025 [1] - The vaccine is indicated for individuals aged three and above, with a specification of 15μg/0.5ml in terms of hemagglutinin concentration [1]
港股异动 | 中慧生物-B(02627)再涨超20% 四价流感病毒亚单位疫苗入选商保创新药目录初审名单